"With significantly strengthened penalties, standardized reporting requirements and unprecedented enforcement commitments, the regulatory landscape has dramatically shifted," the AMA wrote. 

Researchers tracked the rates of major gastrointestinal bleeding in patients with AFib randomized to receive edoxaban or a vitamin K antagonist after a successful TAVR procedure.

COVID-19 vaccines are associated with a very low risk of myocarditis and/or pericarditis, primarily in young adults. The long-term impact of this risk has been the subject of many studies and debates over the years. One side says that the benefits of vaccination far outweigh the risks, and the other side says that even the smallest risk of heart damage is too high.

ACT-EARLY is testing the hypothesis that treating asymptomatic carriers of a pathogenic TTR variant with the drug acoramidis could delay amyloidosis from developing.

"These results highlight semaglutide’s early action on decreasing major cardiovascular events," one cardiologist explained.

Cytokinetics announced positive results from a new clinical trial comparing aficamten monotherapy to the beta blocker metoprolol.

Researchers shared new studies on the highly selective CETP inhibitor in The New England Journal of Medicine and The Lancet.

Researchers evaluated data from more than 273,000 patients with a history of ASCVD, noting that higher Lp(a) levels are consistently linked to worse cardiovascular outcomes.